menu
    • menu
    [{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Aldesleukin","moa":"Il-2 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Porton Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Asparaginase","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Lyophilized Solution","sponsorNew":"Clinigen Group \/ Clinigen","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Clinigen"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"Il-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clinigen Group \/ Not Applicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"Il-2 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Not Applicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Clinigen Group \/ SYNAIRGEN","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen Group \/ SYNAIRGEN"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexrazoxane","moa":"Topoisomerase II","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Not Applicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Humanigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"Clinigen Group \/ Clinigen Group"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen Group \/ Not Applicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Not Applicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Divestment","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Dexrazoxane","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clinigen Group \/ CNX Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen Group \/ CNX Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Clinigen Group

    Menu

    Clinigen Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexrazoxane

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : CNX Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics

                            Details : Under the terms of the divestment, Clinigen will divest four medicines, Cardioxane (dexrazoxane), Savene, Totect and Ethyol, all of which help mitigate the side effects patients may experience when treated with other cancer therapies, to CNX Therapeutics...

                            Brand Name : Cardioxane

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 10, 2023

                            Lead Product(s) : Dexrazoxane

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : CNX Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Iovance Biotherapeutics

                            Deal Size : $206.3 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Clinigen Divests Proleukin® to Iovance Biotherapeutics for £166.7 million

                            Details : Proleukin® (aldesleukin), a form of interleukin-2, is indicated for the treatment of adults with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC).

                            Brand Name : Proleukin

                            Molecule Type : Large molecule

                            Upfront Cash : $206.3 million

                            January 23, 2023

                            Lead Product(s) : Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Iovance Biotherapeutics

                            Deal Size : $206.3 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinigen Initiates A Managed Access Program For Relugolix In Europe For The Treatment Of Advanced Hormone-sens...

                            Details : Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

                            Brand Name : Orgovyx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2022

                            Lead Product(s) : Relugolix

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldesleukin,Riluzole

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinigen Notes Results from The MIROCALS Trial Investigating Low Dose Proleukin® (aldesleukin) In Patients wi...

                            Details : Clinigen confirms that Proleukin, interleukin-2 (aldesleukin), supplied for the MIROCALS trial, is currently licensed for metastatic renal cell carcinoma and melanoma in the US and metastatic renal cell carcinoma in certain other countries.

                            Brand Name : Proleukin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 08, 2022

                            Lead Product(s) : Aldesleukin,Riluzole

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Humanigen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Humanigen Launches Managed Access Program for Lenzilumab

                            Details : Humaneered (lenzilumab), is an investigational product that is not currently authorized or approved in any country, now available for certain hospitalized COVID-19 patients through its newly-launched LenzMAP.

                            Brand Name : Humaneered

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 09, 2022

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Humanigen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexrazoxane

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinigen’s Totect® Receives FDA Approval for New Indication to Treat Incidence and Severity of Cardiomyopat...

                            Details : Totect® now can be used for reducing the incidence and severity of cardiomyopathy associated with doxorubicin in women with breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy.

                            Brand Name : Totect

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 10, 2020

                            Lead Product(s) : Dexrazoxane

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Synairgen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Synairgen and Clinigen Sign Managed Access Program Agreement with SNG001 for Treatment of Hospitalised Patient...

                            Details : The collaboration will be working to progress SNG001 through the required clinical and regulatory channels to make this potentially critical treatment widely available to COVID-19 patients around the world.

                            Brand Name : SNG001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 29, 2020

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Synairgen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldesleukin

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinigen's ALS Therapy Bags US Orphan Status

                            Details : According to the firm, the ODD recognises the potential therapeutic role of aldesleukin in treating disease, and could provide a number of benefits for Clinigen should it obtain a marketing approval for this indication.

                            Brand Name : Proleukin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 13, 2020

                            Lead Product(s) : Aldesleukin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2,Tumor infiltrating lymphocyte,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinigen Demonstrates IL-2 Plays Role in Emerging TIL Therapies

                            Details : Study aimed at evaluating the safety and efficacy of TIL therapy in metastatic NSCLC (mNSCLC) after evidence of progression on nivolumab.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 04, 2020

                            Lead Product(s) : Interleukin 2,Tumor infiltrating lymphocyte,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Clinigen Group

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asparaginase

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Porton Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Porton Biopharma Limited Licenses Erwinase® to Clinigen

                            Details : Under the terms of the agreement, Clinigen will distribute Erwinase®/ Erwinaze®, the Porton's life-saving treatment for acute lymphoblastic leukaemia.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 16, 2020

                            Lead Product(s) : Asparaginase

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Porton Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth